HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Castiglioni, F Articles by Ménard, S Search for Related Content PubMed PubMed Citation Articles by Castiglioni, F Articles by Ménard, S

Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
¹ Institute of Pathology, University of Milan, Milan, Italy

(Requests for offprints should be addressed to S Ménard; Email sylvie.menard{at}istitutotumori.mi.it)

A splice variant of the human gene HER2, lacking exon-16 (HER2) which encodes a small extracellular region, has been described. This altered receptor forms disulfide bond-stabilized homodimers. We report here that the HER2 splice variant represents about 9% of the HER2 mRNA obtained from most of the 46 breast carcinoma samples with HER2 expression levels ranging from 3+ to 0 by HercepTest. Analysis of human cells transfected with HER2 or wild-type (WT) cDNA revealed no growth of WT cells in nude mice, whereas clones expressing 10-fold less HER2 were tumorigenic. Unlike WT transfectants, HER2-expressing cells showed low sensitivity to two new therapeutic drugs targeting receptors of the HER family (ZD1839 and Trastuzumab), whereas an inhibitor of the HER2 tyrosine kinase domain (Emodin) blocked activation of both HER2 and WT transfectants. Taken together, our findings indicate that the HER2 transcript encodes the transforming form of the oncoprotein. It is plausible that malignant transformation arises when a critical threshold of HER2 is reached in HER2-overexpressing tumors. Specific inhibitors of HER2 catalytic activity represent a promising approach to therapy of HER2-overexpressing tumors.

This article has been cited by other articles:

				X. Huang, L. Gao, S. Wang, J. L. McManaman, A. D. Thor, X. Yang, F. J. Esteva, and B. Liu Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin Cancer Res., February 1, 2010; 70(3): 1204 - 1214. [Abstract] [Full Text] [PDF]

				D. Mitra, M. J. Brumlik, S. U. Okamgba, Y. Zhu, T. T. Duplessis, J. G. Parvani, S. M. Lesko, E. Brogi, and F. E. Jones An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance Mol. Cancer Ther., August 1, 2009; 8(8): 2152 - 2162. [Abstract] [Full Text] [PDF]

				A. Magnifico, L. Albano, S. Campaner, D. Delia, F. Castiglioni, P. Gasparini, G. Sozzi, E. Fontanella, S. Menard, and E. Tagliabue Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab Clin. Cancer Res., March 15, 2009; 15(6): 2010 - 2021. [Abstract] [Full Text] [PDF]

				A. Magnifico, L. Albano, S. Campaner, M. Campiglio, S. Pilotti, S. Menard, and E. Tagliabue Protein Kinase C{alpha} Determines HER2 Fate in Breast Carcinoma Cells with HER2 Protein Overexpression without Gene Amplification Cancer Res., June 1, 2007; 67(11): 5308 - 5317. [Abstract] [Full Text] [PDF]

				S. M. Pupa, S. Giuffre, F. Castiglioni, L. Bertola, M. Cantu, I. Bongarzone, P. Baldassari, R. Mortarini, W. S. Argraves, A. Anichini, et al. Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1 Cancer Res., May 1, 2007; 67(9): 4271 - 4277. [Abstract] [Full Text] [PDF]